Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents |
| |
Authors: | Larochelle P Kollmannsberger C Feldman R D Schiffrin E L Poirier L Patenaude F Ruether D Myers M Bjarnason G |
| |
Affiliation: | Institut de recherches cliniques de Montréal, Montreal, QC. |
| |
Abstract: | Inhibitors of the vascular endothelial growth factor (vegf-is) signalling pathway have fundamentally changed the treatment of metastatic renal cell carcinoma (mrcc). Hypertension is one of the most common side effects of vegf-is and has been reported with almost every vegf-i used for treatment to date. The exact mechanism of vegf-i-induced hypertension appears complex and multifactorial, and it remains to be fully explained. No randomized clinical trials are available to guide the management of hypertension during vegf-i treatment in mrcc patients. The guiding principles suggested here summarize the consensus of opinions on the diagnosis and management of vegf-i-induced hypertension during treatment of mrcc obtained from an expert working group composed of 4 Canadian medical oncologists and 5 Canadian hypertension specialists. The Canadian Hypertension Education Program guidelines, available literature, and expert opinion were used to develop the guiding principles. |
| |
Keywords: | Vascular endothelial growth factor inhibitors hypertension metastatic renal cell carcinoma |
本文献已被 PubMed 等数据库收录! |